<DOC>
	<DOC>NCT00225056</DOC>
	<brief_summary>In this phase II study, we plan to evaluate the efficacy, safety and tolerability of weekly docetaxel and capecitabine on a 21-day cycle followed by maintenance single agent capecitabine for the treatment of metastatic breast cancer, Based on the efficacy and toxicity of the combination regimen dosages previously reviewed; weekly docetaxel 30mg/m2 on days 1 and 8 plus capecitabine 1600mg/m2 (800mg/m2 orally twice daily)on day 1 through 14 of each cycle will be utilized.</brief_summary>
	<brief_title>Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>must have metastatic breast cancer must have cytologically or pathologically confirmed invasive ductal or lobular carcinoma must have measurable or evaluable disease ECOG of 01 patients may have received 0, 1. or 2 prior treatments for metastatic breast cancer must have adequate organ function must be at least 19 years of age peripheral neuropathy less than or equal to grade 1 must have voluntarily signed informed consent patients with brain metastases are eligible provided that other measurable disease exists and brain lesions are controlled patients with other malignancies, except non melanoma of the skin, who have had any evidence of cancer within the last 5 years patients with psychiatric illness or other concurrent severe comorbid medical condition that would preclude study completion known uncontrolled existing coagulopathy patients with a history of severe hypersensitivity reaction to docetaxel, medications formulated with polysorbate 80 or 5fluorouracil use of other investigational agents in the last 28 days pregnant or lactating women patients who are known HIV positive patients with life expectancy of less than 3 months sexually active patients unwilling to practice reliable contraception during the study</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>